Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAytu BioScience Inc

Aytu BioScience Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
1.84 USD 0.01 ( 0.55%)
Last update at 2026-11-09T15:41:00Z
VOLUME
20882
Market Cap
27.69M

Momentum Score

…

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.82
Low
1.93
High
52 Week Price Range
1.04
Low
3.07
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Aytu BioScience is a commercial-stage specialty pharmaceutical company that acquires, develops and markets prescription and consumer health products in the United States. Long-term growth may be driven by expanding its product portfolio through acquisitions and by successful commercialization and regulatory progress of pipeline assets; this could provide small-cap exposure to potential revenue upside.

The company faces material risks from limited scale, ongoing operating losses and a likely need for additional financing to support commercialization and pipeline development, which could dilute shareholders and constrain growth.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.83
Dividend Yield
-
Revenue TTM
62.64M
Revenue Per Share
7.73
Gross Profit TTM
41.87M
Debt / Equity
1.21
ROE
-109.23%
Net Debt
-8.02M
ROCE
-16.43%
Diluted EPS TTM
-3.44

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -13.74M -10.38M -17.05M -110.28M -58.03M
Net income -13.56M -15.84M -17.05M -110.17M -58.29M
Selling general administrative 17.38M 19.95M 28.63M 31.17M 25.50M
Selling and marketing expenses 20.91M 22.08M 41.45M 38.71M 30.31M
Gross profit 45.83M 49.05M 66.63M 52.28M 29.20M
Reconciled depreciation 5.38M 8.27M 4.79M 10.25M 9.20M
Ebit -10.04M -5.32M -12.39M 37.22M -38.24M
Ebitda -4.67M 1.41M -7.60M 41.28M -14.49M
Depreciation and amortization 5.38M 6.72M 4.79M 4.07M 23.75M
Operating income -7.83M -1.59M -17.07M 37.22M -38.24M
Other operating expenses 74.21M 66.77M 119.73M 132.77M 103.87M
Interest expense 3.70M 4.79M - 147.50M 37.53M
Tax provision 0.44M 1.77M 0.00M -0.11M 0.26M
Net interest income -3.70M -4.79M - - -
Income tax expense 0.44M 2.14M -0.06M -0.11M 0.26M
Total revenue 66.38M 65.18M 107.40M 96.67M 65.63M
Total operating expenses 53.66M 50.65M 78.96M 88.39M 67.44M
Cost of revenue 20.55M 16.13M 40.77M 44.39M 36.43M
Total other income expense net -5.92M -8.79M -4.72M -147.50M -19.79M
Net income from continuing ops -14.18M -15.84M -17.05M -110.17M -58.29M
Net income applicable to common shares - - -17.05M -110.17M -58.29M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 124.18M 118.09M 136.46M 137.62M 265.67M
Intangible assets 42.20M 52.45M 58.97M 70.63M 85.46M
Other current assets 5.64M 5.63M 0.87M 0.63M 1.04M
Total liab 105.21M 90.38M 97.11M 91.53M 128.10M
Total stockholder equity 18.97M 27.72M 39.36M 46.09M 137.57M
Other current liab 41.41M 47.54M 7.09M 49.55M 7.41M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -333.54M -319.97M -304.13M -288.47M -178.30M
Other liab - - 13.38M 12.81M 15.86M
Good will - - - 0.00M 65.80M
Other assets - - 0.79M 0.77M 0.47M
Cash 30.95M 20.01M 22.98M 19.36M 49.65M
Total current liabilities 63.06M 62.23M 69.02M 64.44M 109.44M
Current deferred revenue - 38.57M 46.80M - 57.23M
Net debt -8.02M -4.88M -6.62M -1.17M -21.30M
Short term debt 11.06M 4.25M 1.65M 3.91M 25.54M
Short long term debt 10.92M 4.25M 1.65M 3.91M 24.60M
Short long term debt total 22.94M 15.13M 16.36M 18.19M 28.35M
Other stockholder equity 352.50M 347.69M 343.49M 334.56M 315.86M
Property plant equipment - - 3.87M 6.30M 8.70M
Total current assets 79.18M 61.89M 72.83M 59.93M 105.23M
Net tangible assets - - -19.61M -24.54M -13.70M
Net receivables 31.16M 23.62M 28.94M 21.71M 28.18M
Long term debt 10.89M 10.88M 14.71M 14.28M 0.18M
Inventory 11.43M 12.63M 11.99M 10.85M 16.34M
Accounts payable 10.60M 10.44M 13.48M 10.99M 19.25M
Common stock total equity - - - - 0.00M
Non currrent assets other 1.20M 2.23M 0.79M 0.77M 0.47M
Non current assets total 45.00M 56.20M 63.63M 77.69M 160.43M
Capital lease obligations - - - - 3.56M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -2.56M -0.33M -0.12M -3.25M -2.78M
Change to liabilities - - 2.38M -7.68M -3.25M
Total cashflows from investing activities -2.56M -0.33M -0.12M -3.25M -2.78M
Net borrowings 6.67M -1.89M -2.35M -5.22M -3.74M
Total cash from financing activities 15.44M -1.26M 8.87M 1.53M 30.31M
Change to operating activities - - 2.58M -11.01M 0.60M
Net income -13.56M -15.84M -17.05M -110.17M -58.29M
Change in cash 10.95M -2.98M 3.62M -30.54M 1.57M
Begin period cash flow 20.01M 22.98M 19.36M 49.90M 48.33M
End period cash flow 30.95M 20.01M 22.98M 19.36M 49.90M
Total cash from operating activities -1.94M -1.39M -5.13M -28.82M -25.96M
Issuance of capital stock 14.84M 3.47M 15.57M 11.69M 45.05M
Depreciation 5.38M 6.72M 8.81M 10.25M 9.20M
Other cashflows from investing activities -2.33M -0.33M -0.11M -0.07M 0.04M
Change to inventory 0.38M -4.82M -3.61M 1.30M 2.79M
Change to account receivables -7.63M 5.20M -7.15M 6.53M 1.54M
Other cashflows from financing activities -6.07M -2.84M -4.36M 162.29M 40.21M
Change to netincome - - 8.90M 81.96M 21.44M
Capital expenditures 3.23M 0.33M 0.00M 0.00M 2.34M
Change in working capital -5.73M -4.66M -5.80M -10.86M 1.68M
Stock based compensation 0.58M 2.37M 6.05M 5.25M 3.57M
Other non cash items 11.40M 10.02M -0.40M 76.71M -4.46M
Free cash flow -5.17M -1.72M -5.13M -28.82M -25.96M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
AYTU
Aytu BioScience Inc		 0.01
0.55%		 1.84 - 3.69 0.44 1.95 0.30 1.14
MKKGY
Merck KGaA ADR		 0.49
1.48%		 33.66 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -2.76
1.62%		 167.12 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.05
0.24%		 20.97 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 0.50
1.19%		 42.35 - 10.66 0.01 1.16 2.94 23.11

Profile*

Aytu BioScience Inc

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

Denver Corporate Center III, Denver, CO, United States, 80237

720 437 6580

https://aytubio.com

82

Name Title Year Born
Mr. Joshua R. Disbrow Chairman & CEO 1975
Mr. Mark K. Oki CPA CFO, Sec. & Treasurer 1969
Mr. Christopher Brooke Chief Operating Officer NA
Mr. Jarrett T. Disbrow Ph.D. Chief Bus. Officer & Pres of Consumer Health 1975
Mr. Greg Pyszczymuka Chief Commercial Officer NA
Mr. Russ McMahen Sr. VP of R&D NA
Mr. Ryan J. Selhorn CPA Exec. VP of Fin. & Bus. Optimization 1982
Mr. Mark K. Oki CPA CFO, Secretary & Treasurer 1969
Mr. Greg Pyszczymuka Chief Commercial Officer 1979
Ms. Victoria Cordova Vice President of People & Culture NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.93
+37.83%
MOON
CAD 4.86
+10.20%
HG
CAD 4.43
+9.93%
EPRX
CAD 10.57
+8.86%
NUAG
CAD 8.66
+8.79%
CSU
CAD 3257.60
-7.63%
DIV
CAD 3.85
-5.53%
TOI
CAD 99.00
-5.52%
BSX
CAD 0.82
-4.65%
LMN
CAD 26.79
-4.63%

Equity Sectors*

  • Basic Materials

    +3.88%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.16%

  • Financial Services

    +1.33%

  • Healthcare

    +1.50%

  • Industrials

    +2.97%

  • Real Estate

    +0.41%

  • Technology

    +1.27%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…